The Made-in-Italy Fast-Track Acceleration Program Dedicated to Projects in Life Science

ZCube, Research Venture of the pharmaceutical group Zambon, announced the second edition of Open Accelerator, the made-in-Italy fast track acceleration program dedicated to projects in life science fields. Open Accelerator is a 12-steps program providing training to international researchers, scientists and aspiring entrepreneurs that following a selection could receive a seed investment of up to a maximum of 100.000 EUR for each project.

The call for ideas is open until 16 July 2017 and it covers four main areas of interest:

  • Drug delivery systems (systems that allow better drug delivery either through particles or devices);
  • Open source prototyping: medical devices, biomarkers, diagnostics (Instruments and devices that allow safe and effective treatment, rehabilitation, prevention and diagnosis of diseases);
  • Wearables and digital health (technological solutions through wearable devices that improve the cure of diseases; technological platforms or mobile applications that offer new solutions to improve patient's health)
  • Big data (projects related to the data analysis and solutions to improve medical treatment, develop personalized medicine, identify new markers for early diagnosis and that reduce healthcare costs).

"For many years ZCube has been committed to developing partnerships in the field of scientific research through an open approach which aims at establishing relationships with international researchers, centers of excellence and universities around the world," declares Elena Zambon, President of Zambon Spa. "Open Accelerator is an evolution of ZCube created to sustain scientific and digital innovation, the latter being a great agent of change of our times especially in the healthcare sector."

The program is available through the website http://www.openaccelerator.it. A maximum of 30 projects will be selected to participate in the acceleration program that offers training andsupport by mentors and specialized advisors, including entrepreneurs, business angels, venture capitalists and experts from different areas.

The acceleration path is open to researchers and scientists that have the ambition to conduct translational science. The program will be based on the established methodology of the Business Model Canvas that has been adopted by the National Science Foundation (NSF) and the National Institute of Health (NIH) in the United States.

Moreover, ZCube has recently signed a partnership with IAB - Italian Angels for Biotech, the first association of business angels exclusively dedicated to Life Sciences- and Innogest, a leading venture capital fund operating in Italy and in Europe. Advisors from IAB and Innogest, along with other international experts, will participate in the acceleration path providing mentorship and advisory to guide startuppers through the business model creation and and go-to-market strategy development. At the end of the program the most innovative ideas could receive a seed investment of up to Euro 100.000, which will serve as an important catalyst to enter the market.

"Open Accelerator is an arena in which researchers and entrepreneurs are helped to build the foundation of their startups and to prepare for the challenge of reaching out to venture capital that will finance the next stages of their projects," concludes Elena Zambon. "Our accelerator program will become the heart of Open Zone, the scientific campus located near Milan where science oxygenates business. Open Zone is a community of 600 people where new projects, talents and proven expertise come together to help affirming the role of Italy as an ideal country for business innovation."

For further information and to apply, please visit:
http://www.openaccelerator.it

About ZCube Research Venture Zambon Group
For over a decade ZCube has been active in the exploration of innovative technologies with a profile of technology scouting & brokerage at international level. With an experienced team and network of entrepreneurs, business angels and venture capital, ZCube invests in- and supports innovative ideas from early stages of development up to market launch in the fields of drug delivery, medical devices and digital health. ZCube uses a satellite "open source" research model developed by Zambon in order to develop specialized and innovative products in the areas of the company’s therapeutic interest through collaborations with biotech companies, international research centers and universities.

About Open Zone
Open Zone is a scientific campus near Milan with over 7500mq of laboratories and offices 15.550mq, hosting 22 companies operating in the field of biotechnology and Life Sciences. Open Zone is a place where knowledge is shared amongst multiple partners in the life science to foster innovation, synergy and shared development as well as a place aimed at fostering the development of relationships with the community at large. Open Zone is also home to the Museum Zambon and Oxy.gen, a futuristic air-bubble shaped building created from an idea of the Zambon Group and designed by the architect Michele De Lucchi as a place of science associated with breathing.

About Zambon
Zambon is a leading Italian pharmaceutical and fine-chemical multinational company that has earned a strong reputation over the years for high quality products and services. Zambon is well-established in 3 therapeutic areas: respiratory, pain and women’s health, and is very strongly committed to its entry into the CNS space with Xadago® (safinamide) for the treatment of Parkinson’s disease and rare diseases with Promixin® in cystic fibrosis. Zambon is headquartered in Milan and was established in 1906 in Vicenza. Zambon is present in 19 countries with subsidiaries and almost 2,800 employees with manufacturing units in Italy, Switzerland, France, China and Brazil. Zambon products are commercialized in 84 countries.

Most Popular Now

Top 20 Breaking eHealth News of 2017

eHealthNews.eu is proud to announce the top 20 most popular eHealth News from 2017. Have a wonderful 2018 new(s) year filled with health, happiness, and spectacular success!

Smartphone Health Apps Miss Some Daily A…

If you use your smartphone to monitor your physical activity, you're probably more active than it suggests. A new UBC study finds that the iPhone's built-in pedometer missed about 1,340...

Open Call SC1-DTH-08-2018: Prototyping a…

Large amounts of valuable health data are generated and collected during and between citizens' medical examinations across Europe. However, opportunities to reuse these data for research and better healthcare are...

conhIT Newcomer Award 2018: The Search i…

17 - 19 April 2018, Berlin, Germany. Be it robotics experts or software developers for 'paper-free hospitals', the digitisation of the healthcare system means that medical IT specialists are in short...

Ophthalmologists Increasingly Dissatisfi…

Ophthalmologists' use of electronic health records (EHR) systems for storing and accessing patients' medical histories more than doubled between 2006 and 2016, while their perceptions of financial and clinical productivity...

Philips and American Well form global pa…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and American Well™, the leading U.S. telehealth provider that connects millions of consumers with care professionals through video...

No Cash, No Staff: How can the NHS Affor…

Opinion Article by Leesa Ewing, Commercial Director, IMS MAXIMS. Ongoing news of an NHS 'cash flow crisis' has continued to appear in the media in recent weeks, despite new funding pledges...

Researchers Develop a Remote-Controlled …

A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells...

Scientists Design Bacteria to Reflect 'S…

In the 1966 science fiction film Fantastic Voyage, a submarine is shrunken down and injected into a scientist's body to repair a blood clot in his brain. While the movie...